Abizer Gaslightwala, CEO, joined by Dr. Satya Mitra, Head of Oncology, and Senior Scientist Dr. Mastewal Abuhay, to discuss the advancement of our innovative ADC technology with our proprietary spliceosome payload, which has the potential for superior tumor-killing activity.

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series bit.ly/4g4eOcJ $AKTX #AntibodyDrugConjugates #Oncology #VirtualInvestor @investorvirtual

📅 Save the Date! $AKTX will participate in a #VirtualInvestor Closing Bell segment on September 4th at 4 PM ET. Don't miss it— register here: bit.ly/3HUDJ5S #Oncology #ADCs #AntibodyDrugConjugates @investorvirtual

Don’t Miss This! 🚨 #TuneInTomorrow at 4 PM ET for a live corporate update and Q&A during our #VirtualInvestor Closing Bell segment. Get the latest insights and have your questions answered in real time. Register now: bit.ly/3HUDJ5S #AKTX #Oncology @investorvirtual

#HappeningToday at 4 PM ET! #AKTX participates in a #VirtualInvestor Closing Bell event featuring Abizer Gaslightwala, Director, President & CEO. Don’t miss this live corporate update and Q&A! Access the event here: bit.ly/3HUDJ5S #Oncology #ADCs @investorvirtual

#StartingSoon: Hear the latest from our leadership team during a #VirtualInvestor Closing Bell segment at 4 PM ET — and have your questions answered in a live, interactive Q&A. Join us here: bit.ly/3HUDJ5S $AKTX #Oncology #ADCs @investorvirtual

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference bit.ly/46p6hxC $AKTX #AntibodyDrugConjugates #Oncology

🚨 Now Available! $AKTX’s presentation from the H.C. Wainwright 27th Annual Global Investment Conference is now available to watch on demand. Don’t miss it — tune in now: bit.ly/4prt1or #AntibodyDrugConjugates #ADCs #Oncology

CEO Abizer Gaslightwala shared insights on our PH1 Spliceosome Modulating Payload and its potential to transform cancer therapy during the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. Watch the full presentation here: bit.ly/4mY001W $AKTX #ADCs

#InCaseYouMissedIt: Abizer Gaslightwala, Director, President & CEO, joined a #VirtualInvestor Closing Bell segment to share a corporate update and take part in an interactive Q&A. 🎥 Watch the replay here: bit.ly/3HUDJ5S $AKTX #Oncology #ADCs @investorvirtual

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer bit.ly/3KoVlaC $AKTX #AntibodyDrugConjugates #Oncology

Why Akari Therapeutics? Take a look at our latest corporate presentation to learn more: bit.ly/4nbt7hO $AKTX #AntibodyDrugConjugates #ADCs #Oncology

CEO Abizer Gaslightwala joined a #VirtualInvestor #WhatThisMeans segment to discuss our novel spliceosome modulator payload and its potential to target key cancer-driving mechanisms. 🎥 Watch the full discussion here: vimeo.com/1105434643/5e1… $AKTX #AntibodyDrugConjugates #ADCs

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 bit.ly/4gEN7XX $AKTX #AntibodyDrugConjugates #ADCs

CEO Abizer Gaslightwala, shares excitement around preclinical data supporting the development of a novel ADC with our PH1 spliceosome-modulating payload. The goal is to advance the first ADC therapeutic in prostate cancer, addressing a major unmet need. bit.ly/4gEN7XX

Focused on Innovating Antibody Drug Conjugates as Immuno-Oncology Therapies for Patients to Be Cancer Free $AKTX #AntibodyDrugConjugates #ADC #Oncology

#CatchTheReplay: Abizer Gaslightwala, Director, President & CEO of Akari Therapeutics, recently joined the #VirtualInvestor Closing Bell to provide a corporate update and participate in a live Q&A. 🎥 Watch here: bit.ly/3HUDJ5S $AKTX #Oncology #ADCs @investorvirtual

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting bit.ly/4mNrIxo $AKTX #AntibodyDrugConjugates #ADC #Oncology

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 bit.ly/4h5AsOj $AKTX #AntibodyDrugConjugates #ADC #Oncology

Current cancer therapies often fall short, leaving significant unmet needs. At Akari, we are focused on innovating therapies with the goal of helping patients be cancer free. $AKTX #AntibodyDrugConjugates #ADC #Oncology